PMID- 34160474
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 2328-8957 (Print)
IS  - 2328-8957 (Electronic)
IS  - 2328-8957 (Linking)
VI  - 8
IP  - 6
DP  - 2021 Jun
TI  - Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of 
      Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the 
      OPTIC Study.
PG  - ofab135
LID - 10.1093/ofid/ofab135 [doi]
LID - ofab135
AB  - BACKGROUND: Severity/mortality risk scores and disease characteristics may assist 
      in deciding whether patients with community-acquired bacterial pneumonia (CABP) 
      require outpatient treatment or hospitalization. The phase 3 OPTIC (Omadacycline 
      for Pneumonia Treatment In the Community) study enrolled patients with Pneumonia 
      Outcomes Research Team (PORT) risk class II-IV. Omadacycline demonstrated 
      noninferiority to moxifloxacin in adults with CABP, at early clinical response 
      (ECR) and posttreatment evaluation (PTE). We assessed efficacy of omadacycline 
      versus moxifloxacin in these patients based on disease severity. METHODS: 
      Patients were randomized 1:1 to receive intravenous (IV) omadacycline (100 mg 
      every 12 hours for 2 doses followed by 100 mg daily [q24h], with optional 
      transition to omadacycline 300 mg orally q24h after 3 days of IV treatment) or 
      moxifloxacin IV 400 mg q24h (with optional transition to 400 mg orally q24h after 
      3 days of IV treatment). Total treatment duration was 7-14 days. We compared 
      rates of early clinical success (72-120 hours after first dose) and 
      investigator-assessed clinical success at PTE (5-10 days after last dose) in 
      subgroups based (1) on severity/mortality risk scores (PORT, CURB-65, systemic 
      inflammatory response syndrome, quick Sequential [Sepsis-related] Organ Failure 
      Assessment, modified ATS, SMART-COP) and (2) on presence of baseline radiographic 
      characteristics, chronic obstructive pulmonary disease (COPD)/asthma, or 
      bacteremia. RESULTS: Altogether, 774 patients (omadacycline, n = 386; 
      moxifloxacin, n = 388) were randomized. Clinical success rates (ECR/PTE) were 
      similar between treatment groups (across all subgroups). Efficacy across 
      treatment groups was similar in patients with baseline radiographic 
      characteristics or COPD/asthma, but moxifloxacin had higher clinical success 
      rates in patients with bacteremia. CONCLUSIONS: Efficacy of omadacycline was 
      similar to that of moxifloxacin, regardless of disease severity/mortality risk 
      and disease characteristics.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of 
      Infectious Diseases Society of America.
FAU - Ramirez, Julio
AU  - Ramirez J
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      Louisville, Louisville, Kentucky, USA.
FAU - Deck, Daniel H
AU  - Deck DH
AD  - Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
FAU - Eckburg, Paul B
AU  - Eckburg PB
AD  - Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
FAU - Curran, Marla
AU  - Curran M
AD  - Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
FAU - Das, Anita F
AU  - Das AF
AD  - AD Stats Consulting, Guerneville, California, USA.
FAU - Kirsch, Courtney
AU  - Kirsch C
AD  - Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
FAU - Manley, Amy
AU  - Manley A
AD  - Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
FAU - Tzanis, Evan
AU  - Tzanis E
AD  - Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
FAU - McGovern, Paul C
AU  - McGovern PC
AD  - Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20210618
PL  - United States
TA  - Open Forum Infect Dis
JT  - Open forum infectious diseases
JID - 101637045
CON - Open Forum Infect Dis. 2021 Jun 18;8(6):ofab136. PMID: 34160473
PMC - PMC8212944
OTO - NOTNLM
OT  - community-acquired bacterial pneumonia
OT  - moxifloxacin
OT  - omadacycline
OT  - severity
EDAT- 2021/06/24 06:00
MHDA- 2021/06/24 06:01
PMCR- 2021/06/18
CRDT- 2021/06/23 12:20
PHST- 2020/09/10 00:00 [received]
PHST- 2021/03/25 00:00 [accepted]
PHST- 2021/06/23 12:20 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/06/24 06:01 [medline]
PHST- 2021/06/18 00:00 [pmc-release]
AID - ofab135 [pii]
AID - 10.1093/ofid/ofab135 [doi]
PST - epublish
SO  - Open Forum Infect Dis. 2021 Jun 18;8(6):ofab135. doi: 10.1093/ofid/ofab135. 
      eCollection 2021 Jun.